Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832393 | 1.00 | NR5A1 (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL946779 | 1.00 | NR5A1 (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL3924421 | 1.00 | NR5A1 (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL9706419 | 1.00 | NR5A1 (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL4748828 | 1.00 | NR5A1 (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL949228 | 0.98 | NR5A1 (0.58) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL7697232 | 0.95 | RARB (0.58) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10987211 | 0.95 | RARB (0.58) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1007565 | 0.94 | LTA4H (0.53) | NR5A1LTA4HTP53TSHRNPC1 | |
| SCHEMBL10987443 | 0.93 | CYP2D6 (0.56) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244476-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-08-25 | — | — | US | disclosed |
| US-9351970-B2 | Anti-viral pyrimidine nucleoside analogues | REGA FOUNDATION (BE) | 2016-05-31 | — | — | US | disclosed |
| US-20140011764-A1 | Anti-Viral Pyrimidine Nucleoside Analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8551965-B2 | Anti-viral pyrimidine nucleoside analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20110015147-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2011-01-20 | — | — | US | disclosed |
| US-7820631-B2 | Anti-viral pyrimidine nucleoside analogues | REGA FOUNDATION (BE) | 2010-10-26 | — | — | US | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| EP-1274713-B1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIV CARDIFF (GB) | 2004-03-10 | — | — | EP | disclosed |
| US-20030148967-A1 | Anti-viral pyrimidine nucleoside analogues | REGA FOUNDATION (BE) | 2003-08-07 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| EP-1274713-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | University College Cardiff Consultants Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001083501-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-11-08 | — | — | WO | disclosed |
| EP-0308438-B1 | LIQUID CRYSTAL PHASE CONTAINING TOLANES | MERCK PATENT GmbH (DE) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015147-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | NSUN2, PNP, TDO2 | NR5A1 2126/4885LTA4H 2346/4885TP53 1808/4885 |
| US-20140011764-A1 | Anti-Viral Pyrimidine Nucleoside Analogues | NSUN2, HCN2, TK1 | NR5A1 1907/4885LTA4H 2515/4885TP53 1871/4885 |
| US-20030148967-A1 | Anti-viral pyrimidine nucleoside analogues | NUDT1, DNTT, RNMT | NR5A1 831/4885LTA4H 2687/4885TP53 936/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | NR5A1 459/4885LTA4H 3868/4885TP53 2201/4885 |
| US-20160244476-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | NSUN2, PNP, CCNO | NR5A1 2197/4885LTA4H 2296/4885TP53 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.